Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 10, 2007, Pages 2863-2868

  Zhang, Han Cheng ^a   Boñaga, Llorente V R ^a   Ye, Hong ^a   Derian, Claudia K ^a   Damiano, Bruce P ^a   Maryanoff, Bruce E ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

2+2+2 Cycloaddition; Bis(indolyl)maleimide; Cobalt(I); Heterophane; Inhibition; Macrocycle; Protein kinase

Indexed keywords

ALKYNE DERIVATIVE; BIS(INDOLYL)MALEIMIDE PYRIDINOPHANE; COBALT; CYANAMIDE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; MALEIMIDE DERIVATIVE; PROTEIN SERINE KINASE; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CYCLOADDITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; IC 50; X RAY ANALYSIS;

ADENOSINE TRIPHOSPHATE; BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HYDROPHOBICITY; MALEIMIDES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247352907     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.02.059     Document Type: Article

References (32)

1. Phan L.T., Clark R.F., Rupp M., Or Y.S., Chu D.T.W., and Ma Z. Org. Lett. 2 (2000) 2951 and references therein
2. Resek J.E., Wang X.C., and Bhatia A.V. Curr. Opin. Drug Discov. Dev. 3 (2000) 807
3. Bartlett P.A., Yusuff N., Pyun H.-J., Rico A.C., Meyer J.H., Smith W.W., and Burger M.T. Medicinal Chemistry into the Millennium Vol. 264 (2001), Royal Society of Chemistry, London p. 3
4. Ojima I., Geng X., Lin S., Pera P., and Bernacki R.J. Bioorg. Med. Chem. Lett. 12 (2002) 349
5. Ojima I., Lin S., Inoue T., Miller M.L., Borella C.P., Geng X., and Walsh J.J. J. Am. Chem. Soc. 122 (2000) 5343
6. Tamaoki T., Nomoto H., Takahashi I., Kato Y., Morimoto M., and Tomita F. Biochem. Biophys. Res. Commun. 135 (1986) 397
7. Sorbera L.A., Silvestre J., Rabasseda X., and Castaner J. Drugs Future 25 (2000) 1017
8. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P.C., Bursell S.-E.A., Kern T.S., Ballas L.M., Health L.E., Stramm L.E., Feener E.P., and King G.L. Science 272 (1996) 728
9. Jirousek M.R., Gillig J.R., Gonzalez C.M., Heath W.F., McDonald III J.H., Neel D.A., Rito C.J., Singh U., Stramm L.E., Melikian-Badalian A., Baevsky M., Ballas L.M., Hall S.E., Winneroski L.L., and Faul M.M. J. Med. Chem. 39 (1996) 2664
10. Ruboxistaurin is in late-stage clinical trials for treating diabetic complications; also, a New Drug Application (NDA) was filed with the U.S. Food and Drug Administration (FDA).
11. Bartlett S., Beddard G.S., Jackson R.M., Kayser V., Kilner C., Leach A., Nelson A., Oledzki P.R., Parker P., Reid G.D., and Warriner S.L. J. Am. Chem. Soc. 137 (2005) 11699
12. Zhang H.-C., White K.B., Ye H., McComsey D.F., Derian C.K., Addo M.F., Andrade-Gordon P., Eckardt A.J., Conway B.R., Westover L., Xu J.Z., Look R., Demarest K.T., Emanuel S., and Maryanoff B.E. Bioorg. Med. Chem. Lett. 13 (2003) 3049
13. Kuo G.-H., Prouty C., DeAngelis A., Shen L., O'Neill D.J., Shah C., Connolly P.J., Murray W.V., Conway B.R., Cheung P., Westover L., Xu J.Z., Look R.A., Demarest K.T., Emanuel S., Middleton S.A., Jolliffe L., Beavers M.P., and Chen X. J. Med. Chem. 46 (2003) 4021
14. Zhang H.-C., Ye H., Conway B.R., Derian C.K., Addo M.F., Kuo G.-H., Hecker L.R., Croll D.R., Li J., Westover L., Xu J.Z., Look R., Demarest K.T., Andrade-Gordon P., Damiano B.P., and Maryanoff B.E. Bioorg. Med. Chem. Lett. 14 (2004) 3245
15. O'Neill D.J., Shen L., Prouty C., Conway B.R., Westover L., Xu J.Z., Zhang H.-C., Ye H., Maryanoff B.E., Murray W.V., Demarest K.T., and Kuo G.-H. Bioorg. Med. Chem. 12 (2004) 3167
16. Zhang H.-C., Derian C.K., McComsey D.F., White K.B., Ye H., Hecker L.R., Li J., Addo M.F., Croll D., Eckardt A.J., Smith C.E., Li Q., Cheung W.-M., Conway B.R., Emanuel S., Demarest K.T., Andrade-Gordon P., Damiano B.P., and Maryanoff B.E. J. Med. Chem. 48 (2005) 1725
17. Moretto A.F., Zhang H.-C., and Maryanoff B.E. J. Am. Chem. Soc. 123 (2001) 3157
18. Boñaga L.V.R., Zhang H.-C., Gauthier D.A., Reddy I., and Maryanoff B.E. Org. Lett. 5 (2003) 4537
19. Boñaga L.V.R., Zhang H.-C., and Maryanoff B.E. Chem. Commun. (2004) 2394
20. Boñaga L.V.R., Zhang H.-C., Moretto A.F., Ye H., Gauthier D.A., Li J., Leo G.C., and Maryanoff B.E. J. Am. Chem. Soc. 127 (2005) 3473
21. Grimes C.A., and Jope R.S. Prog. Neurobiol. 65 (2001) 391
22. Kim H.-S., Skurk C., Thomas S.R., Bialik A., Suhara T., Kureishi Y., Birnbaum M., Keaney Jr. J.F., and Walsh K. J. Biol. Chem. 84 (2002) 203
23. Manoukian A.S., and Woodgett J.R. Adv. Cancer Res. 84 (2002) 203
24. 10
25. Kaidanovich O., and Eldar-Finkelman H. Expert Opin. Ther. Targets 6 (2002) 555
26. Wagman A.S., and Nuss J.M. Curr. Pharm. Design 7 (2001) 417
27. Bullock W.H., Magnuson S.R., Choi S., Gunn D.E., and Rudolph J. Curr. Top. Med. Chem. 2 (2002) 915
28. Eldar-Finkelman H. Trends Mol. Med. 8 (2002) 126
29. Dorronsoro I., Castro A., and Martinez A. Expert Opin. Ther. Pat. 2 (2002) 1527
30. Faul M.M., Winneroski L.L., and Krumrich C.A. Tetrahedron Lett. 40 (1999) 1109
31. free = 0.246, 0.295). PDB deposition number 2OW3.
32. The interaction of selective, and nonselective, inhibitors with GSK-3β usually involves key hydrogen bonding of the inhibitor ligand with Asp-133 and Val-135, which reside at the 'hinge region' of the ATP binding site. Bertrand J.A., Thieffine S., Vulpetti A., Cristiani C., Valsasina B., Knapp S., Kalisz H.M., and Flocco M. J. Mol. Biol. 333 (2003) 393